ACAD ACADIA PHARMACEUTICALS INC

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: biopharmaceutical focus on neurological and rare diseases with $1.07B net sales from NUPLAZID and DAYBUE in 2025, up from $958M in 2024
• • New product launch: DAYBUE STIX powder formulation introduced in Q1 2026 for Rett syndrome, offering dosing flexibility and improved patient experience
• • Strategic shift: expanding global footprint with EMA marketing authorization application and re-examination request after negative CHMP vote for trofinetide in Rett syndrome
• • Quantitative highlight: initiated three Phase 2 studies in 2025-2026—remlifanserin for ADP and LBDP, ACP-211 for MDD, and planned ACP-711 Phase 2 start for essential tremor
• • Noteworthy fact: discontinued development of ACP-101 after Phase 3 failure in Prader-Willi syndrome, refocusing resources on neurological and rare disease pipeline

Risk Factors

• • Cybersecurity incident escalation to audit committee requiring coordination among CIDO, Chief Legal Officer, and Senior VP of Finance
• • New CIDO hired August 2025 tasked with integrating cybersecurity risk into overall risk strategy
• • Senior Director of Info Security with decade-long company tenure leads cybersecurity risk management processes
• • Incident response includes cross-functional senior management team and security operations integration
• • Governance oversight involves regular audit committee reviews of cybersecurity threats and mitigation efforts

Management Discussion & Analysis

• • Revenue $1,071.5M in 2025 vs $957.8M in 2024, driven by NUPLAZID and DAYBUE sales, up $113.7M YoY
• • Operating loss driven by R&D expenses $328.8M in 2025 vs $303.2M in 2024; gross-to-net adjustments reduced net sales by $20.1M from Medicare rebate revision
• • Best performing: DAYBUE, contributing significantly with expanded approvals; worst: ACP-101 discontinued post Phase 3 failure
• • Cash inflows included $146.5M Rare Pediatric Disease PRV sale in 2024; capital outlays include $12M upfront and milestone payments in R&D for 2025
• • Forward outlook notes substantial R&D investments continuing for remlifanserin and early-stage candidates; risks include regulatory milestone uncertainties and potential clinical trial delays

What are the latest ACAD SEC filings in 2026?

ACADIA PHARMACEUTICALS INC (ACAD) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did ACAD file its most recent 10-K annual report?

ACADIA PHARMACEUTICALS INC (ACAD) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view ACAD 10-Q quarterly reports?

ACADIA PHARMACEUTICALS INC (ACAD)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every ACAD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has ACAD filed recently?

ACADIA PHARMACEUTICALS INC (ACAD)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find ACAD insider trading activity (Form 4)?

SignalX aggregates every ACAD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does ACAD file with the SEC?

ACADIA PHARMACEUTICALS INC (ACAD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ACAD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ACADIA PHARMACEUTICALS INC (ACAD).

What is ACAD's SEC CIK number?

ACADIA PHARMACEUTICALS INC (ACAD)'s SEC CIK (Central Index Key) number is 1070494. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1070494 to look up all ACAD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find ACAD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from ACADIA PHARMACEUTICALS INC (ACAD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.